% | $
Quotes you view appear here for quick access.

Muscle Pharm Corp. Message Board

  • skeeterklemann skeeterklemann Dec 18, 2013 11:34 AM Flag

    •Muscle Pharm: Shares Are Deeply Undervalued At Current Levels

    MusclePharm (OTCQB:MSLP) is a fast growing sports nutrition company with expected sales of over $100 million for FY 2013 and a market cap of approximately $70 million. Based on my analysis below, I believe there is significant upside potential for the shares over the next 3 months as the company releases FY2014 guidance and updates on the progress on various initiatives that have taken in place in FY2013.
    •The current share price does not reflect the fundamental improvements in the underlying business, which has transformed the company during FY 2013.
    •There is a significant valuation overhang on the shares from the on-going SEC investigation and the pending NASDAQ uplisting, both of which I expect will be resolved within the next 3 months.
    •Currently trading at around $8, the shares appear to be significantly undervalued. Based on conservative assumptions on growth and profitability I derive a fair value of around $14 per share.
    •Recent insider purchases by MusclePharm management and the announcement of a share repurchase program further support this observation.
    •The company's strategic development has been financed by a group of investors led by Phil Frost (CEO and Chairman of Opko Health (OPK)) who invested $2.5 million through a common share offering at $10.50 per share in August of this year. MusclePharm raised $12 million in February 2013 at $8 per share

    SortNewest  |  Oldest  |  Most Replied Expand all replies
2.28-0.02(-0.87%)Aug 26 3:40 PMEDT